Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available. Stryker Corporation, headquartered in Kalamazoo, Michigan, USA, develops, manufactures and markets orthopaedic products, including reconstructive products such as hip, knee and shoulder implants, trauma-related products such as fixation devices, spinal implants, bone cement and biologic products. Stryker also offers medical and surgical equipment such as tools and instruments used in orthopaedics, craniomaxillofacial surgery, functional endoscopic sinus surgery, neurosurgery, spinal surgery and plastic surgery, and hospital furniture and stretchers. In addition, the company provides physical, occupational and speech therapy services through a network of outpatient centres in the US.

Stryker segregates its operations into three reportable segments: Orthopaedic Implants, MedSurg Equipment and Other. The Orthopaedic Implants segment sells orthopaedic reconstructive, trauma and spinal implants, bone cement, the OP-1 bone growth factor and micro implants. The MedSurg Equipment segment sells powered surgical instruments, endoscopic products, hospital beds, stretchers and surgical navigation systems. Other includes the Physical Therapy Services division and corporate activities.

In fiscal 2005, ended 31st December 2005, Stryker achieved strong operating results, with sales rising by 14.3% to US$4.9 billion, led by growth in each business segment. While the company experienced weakness in its US hip business during the year, this was offset by strong growth for its other implants and the MedSurg unit. Stryker's net income was up by 45% to US$675.2 million in 2005, as lower SG&A expenses and cost of sales in relation to the sales growth offset a 32.6% increase in R&D spending to US$279.8 million.

Stryker's principal product area is Orthopaedic Implants, which includes five companies; Stryker Orthopaedics, Stryker Trauma, Stryker Spine, Stryker Biotech and Stryker Leibinger Micro Implants. The business offers reconstructive products such as hip, knee, shoulder and spinal implants, trauma products such as fixation devices, bone cement, biologic products and devices for craniomaxillofacial and hand surgery. In fiscal 2005, the unit accounted for 58.6% of Stryker's total revenue, with sales up by 11.4% to US$2.9 billion, driven by higher shipments of reconstructive, trauma, spinal and micro implant systems, bone cement and the OP-1 bone growth factor.

This company report provides
Executive Summary
An overview of the company, including operating activities and latest results, at a glance key events and strategic focus.
.
Product Portfolio and R&D
Sales analysis and detailed monographs of key products and technology organised by business segment, as well as an insight into the company's research and development.

International Activities
The company's revenues, assets and business activities by geographic region and country.

Appendices
5-year financial assessment
Corporate structure
Key corporate events
Mergers & acquisitions
Agreements
Litigation